一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集

Abstract

Full Text of PDF Full Text of PDF (627k)  required ID / password
Article in Japanese

Original Article

Clinical aspects of coronavirus disease 2019 patients admitted to Tokyo Saiseikai Central Hospital-a comparison between surge 2 and surge 1 patients

Kentaro Fujiia  Morio Nakamurab,*  Taketomo Marukic  Yumi Tsuchiyac  Kazuto Itoc  Daisuke Taniyamac  Kazuhiko Sekined  Makoto Ishiie  Koichi Fukunagae  Takahide Kikuchif 

aDepartment of Nephrology, Tokyo Saiseikai Central Hospital
bDepartment of Pulmonary Medicine, Tokyo Saiseikai Central Hospital
cDepartment of General Internal Medicine, Tokyo Saiseikai Central Hospital
dEmergency & Critical Care Center, Tokyo Saiseikai Central Hospital
eDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine
fDepartment of Hematology, Tokyo Saiseikai Central Hospital
*Present address: Department of Pulmonary Medicine, National Hospital Organization Kanagawa Hospital

ABSTRACT

We retrospectively assessed the clinical status of patients with coronavirus disease 2019 (COVID-19) who were admitted to the Tokyo Saiseikai Central Hospital. Sixty-five patients were enrolled and categorized into either surge 1: patients admitted between March 20 and May 2, 2020 (n = 15) or surge 2: patients admitted between June 4 and August 31, 2020 (n = 50). Fatalities and severity were significantly lower in surge 2. Although the C-reactive protein, lactate dehydrogenase, and D-dimer tests, which are indicators of aggravation, showed a tendency to be lower in surge 2, the patients with sustained high levels of these indicators did not present clinical aggravation. An increase in cases of younger patients and those with less severity, as well as improvements in the laboratory testing system, may have improved the rates of fatality and severity. Moreover, early intervention with drug therapy against COVID-19, such as remdesivir and dexamethasone, may have contributed to the aggravation suppression in surge 2.

KEYWORDS

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)  Coronavirus disease 2019 (COVID-19)  Surge 1 and surge 2 

Received 27 Oct 2020 / Accepted 26 Jan 2021

AJRS, 10(3): 236-244, 2021

Google Scholar